What’s wrong with IP rights? Protecting medicines from competition can be costly
Gram for gram a HIV medicine costs more than gold. What makes drugs so costly? Is it research and development,...
2018 applications open! Online course on reducing barriers to essential medicines in Africa
Applications are open now for this year’s intellectual property (IP) and access to medicines online course. The course is led...
IP-Watch Q&A with Carlos Correa: The myth of IP incentives for all nations
Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property,...
IP-Watch Q&A with Othoman Mellouk: The myth behind health and trade agreements
Othoman Mellouk is the Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC), and campaign...
Civil society key in TRIPS flexibility implementation
Civil society plays an instrumental role in actively defending access to affordable to medicines, making use of TRIPS flexibilities, and...
Ukraine eyes patent law reform after civil society push on medicines access
Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups...
Botswana: Creating (radio) waves to show how intellectual property affects us all
BONELA is raising national awareness as to why intellectual property (IP) and access to medicines are relevant for everyone –...
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: The Summit Highlights
Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....